Advertiser Disclosure: We may earn commissions from partner links at no cost to you. This never affects our editorial content or recommendations.

Healthcare AI NYSE: LLY

Eli Lilly and Company (LLY)

The GLP-1 drug powerhouse racing to put AI-accelerated drug discovery to work.

— loading… 15-min delay · Not financial advice
✓ Reviewed by Get AI Decoded Editorial Team Updated April 2026
← All Healthcare AI Stocks

Sponsored Placement Available

Sponsor this LLY page — reach investors tracking LLY

View Options →

The AI Angle

Eli Lilly is the fastest-growing pharmaceutical company in the world, driven by two blockbuster GLP-1 drugs: Mounjaro (tirzepatide, for type 2 diabetes) and Zepbound (tirzepatide, for obesity). These drugs act on both GIP and GLP-1 receptors simultaneously — a dual mechanism that delivers superior weight loss (15-22%) compared to semaglutide-based drugs. Q4 2025 worldwide revenue hit $19.3 billion, up 43% year-over-year. Lilly guided 2026 full-year revenue to $80–83 billion, implying roughly 30%+ growth from 2025.

Lilly is deploying AI across its drug discovery and clinical trial pipeline to compress development timelines. The company's Mounjaro and Zepbound franchise is the most commercially successful drug launch in pharmaceutical history by revenue trajectory, and the pipeline behind it is equally deep: orforglipron (oral GLP-1 tablet), retatrutide (triple receptor agonist), and AI-driven targets in Alzheimer's, oncology, and immunology. The addressable market for obesity drugs alone is estimated at $100B+ annually — and Lilly is positioned as the dominant supplier.

Key Numbers

$19.3B
Q4 2025 Revenue
+43% YoY; beat $17.96B consensus (CNBC, Feb 4, 2026)
$17.6B
Q3 2025 Revenue
+54% YoY; driven by Mounjaro + Zepbound
$80B–$83B
2026 Revenue Guidance
Company guidance (Lilly IR, Feb 4, 2026)
3/5
AI Exposure Score
Significant AI exposure.
⚡⚡⚡⚡⚡
⚡ About AI Exposure Score: Reflects how central AI is to this company's current revenue and growth strategy. 5 = AI is the core business. 1 = AI is a minor angle. Editorial assessment — not a buy/sell signal.

Get LLY coverage in your inbox

We cover LLY and 24 other AI stocks every morning. Free daily newsletter.

Upcoming Catalysts

  • Orforglipron oral GLP-1 tablet — no injection required, dramatically expands addressable market
  • Retatrutide (triple agonist) Phase 3 data — superior weight loss efficacy vs. Wegovy
  • US government negotiations to expand obesity drug coverage for millions of Americans
  • Manufacturing capacity expansion to meet global demand (multiple new facilities)

Key Risks

  • Novo Nordisk competition intensifying as CagriSema and next-gen semaglutides advance
  • US drug pricing pressure: IRA Medicare negotiation could reduce GLP-1 reimbursement
  • Compounded GLP-1 market from telehealth players (Hims, Ro) eroding branded revenue
  • Supply chain execution: capacity ramp must keep pace with prescription demand

Sources: CNBC (Feb 4, 2026), Lilly IR / PRNewswire (Feb 4, 2026), PRNewswire Q3 (Oct 30, 2025)

⚠️ Not financial advice. This page is for informational purposes only. All figures are sourced from public earnings reports, company guidance, and financial news. Past performance is not indicative of future results. Always do your own research before making any investment decisions.

Trade LLY with a top broker

Open a brokerage account to start trading. We may earn a commission if you use these links — see our disclosure.

R
Robinhood
Commission-free. No minimums.
Open Account →
T
Tastytrade
Built for active traders & options.
Open Account →
W
Webull
Advanced charts. Extended hours.
Open Account →